

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Fremanezumab-vfrm (Ajovy)

#### Notes:

^ Adequate trial is defined as 2 months treatment duration

\* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary **fremanezumab-vfrm (Ajovy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by neurology provider
- Patient is between the ages of 18 and 75 years old
- Prescribed for treatment of chronic migraine or episodic migraine
- Patient has failed an adequate trial<sup>^</sup> of or patient has an allergy or intolerance\* to 3 additional preventative agents for migraine, 2 of which must include: tricyclic antidepressant (amitriptyline or nortriptyline), or beta-blocker (metoprolol or propranolol), or topiramate, or valproate
- Patient does not have cardiac comorbidities including:
  - History of myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, coronary artery bypass surgery, uncontrolled hypertension
- Patient does not have history of the following conditions:
  - Thrombotic event (i.e. deep vein thrombosis or pulmonary embolism)
  - Currently pregnant or breastfeeding

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **fremanezumab-vfrm (Ajovy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- See below criteria for patients stable on medication

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **fremanezumab-vfrm (Ajovy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed for the treatment of migraine (episodic or chronic)
- Patient is between the ages of 18 and 75 years old
- Patient does not have history of the following conditions
  - Thrombotic event (i.e. deep vein thrombosis or pulmonary embolism)
  - Currently pregnant or breastfeeding

kp.org

cps/awc

Revised 10/14/21

Effective 12/02/21

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Fremanezumab-vfrm (Ajovy)

**Continued use criteria for patients stable on the medication:** Non-formulary **fremanezumab-vfrm (Ajovy)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Continued to be prescribed by neurology provider
- Patient does not have cardiac comorbidities including:
  - History of myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, coronary artery bypass surgery, uncontrolled hypertension
- Patient does not have history of the following conditions:
  - Thrombotic event (i.e. deep vein thrombosis or pulmonary embolism)
  - Currently pregnant or breastfeeding